TARGETED DRUGS FOR NSCLC MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-147983 |   Pharmaceuticals and Healthcare

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Targeted Drugs for NSCLC Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL TARGETED DRUGS FOR NSCLC MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL TARGETED DRUGS FOR NSCLC MARKET

7.1 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA TARGETED DRUGS FOR NSCLC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Allergan

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Amgen

16.3 ARIAD Pharmaceuticals (Takeda)

16.4 Beacon Pharma Limited

16.5 BeiGene

16.6 Biocon

16.7 Boehringer-Ingelheim

16.8 Celgene Corporation

16.9 Drug International Limted

16.10 Fujifilm Kyowa Kirin Biologics

16.11 Genvio Pharma Limited

16.12 Hetero Drugs

16.13 ImClone Systems (Eli Lilly)

16.14 Incepta Pharmaceuticals

16.15 Mylan

16.16 Novartis

16.17 Pfizer

16.18 Reliance Lifesciences

16.19 Roche

16.20 AstraZeneca

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET

By Application

Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC

Companies

Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems (Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.